This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Incyte (INCY) Announces Positive Data on Enzyme Inhibitor
by Zacks Equity Research
Incyte Corporation (INCY) recently announced that new data was published from the ongoing trial, ECHO-202 online by the American Society of Clinical Oncology (ASCO).
Concert Pharma Falls After Clinical Hold on Hair Loss Drug
by Zacks Equity Research
Concert Pharmaceuticals, Inc. (CNCE) shares were down almost 8% on Wednesday after the company announced that the FDA has placed a clinical hold on a mid-stage study evaluating its pipeline candidate CTP-543 for the treatment of alopecia areata.
Incyte (INCY) Q1 Loss Narrower than Expected, Revenues Beat
by Zacks Equity Research
Incyte's first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations.
5 Toxic Stocks to Dispose of or Play Short for Profit
by Zacks Equity Research
Just like picking stocks with growth potential, pinpointing toxic stocks and discarding them at the right time is the key to shield your portfolio from big losses or make profits by short selling them.
Should You Get Rid of Incyte Corporation (INCY) Now?
by Zacks Equity Research
Investors may consider dropping the Zacks Rank #4 Incyte Corporation (INCY) stock, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down
by Zacks Equity Research
Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%.
Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed
by Arpita Dutt
Incyte's (INCY) shares were hit by the FDA's complete response letter (CRL) for the company's rheumatoid arthritis drug.
Should You Make a Bet on the Healthcare Stocks?
by Tracey Ryniec
The healthcare industry is much more than Obamacare and drug prices as many companies are using new technologies to create breakthroughs in medicine.
Zacks.com featured highlights: PTC, Covanta Holding, Live Nation Entertainment, Incyte and Vertex Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights: PTC, Covanta Holding, Live Nation Entertainment, Incyte and Vertex Pharmaceuticals
Eli Lilly's Rheumatoid Arthritis Drug Gets CRL in the U.S.
by Zacks Equity Research
Eli Lilly and Company (LLY) and its partner Incyte Corporation (INCY) recently announced that they have received a Complete Response Letter (CRL) from the FDA regarding the new drug application (NDA) for baricitinib.
5 Toxic Stocks to Shun or Play Short Right Now
by Zacks Equity Research
Just like picking up stocks with strong growth potential, pinpointing toxic stocks and abandoning them at the right time is the key to protect your portfolio from big losses or make profits by short selling them.
Agenus (AGEN) Sharpens Focus on Drug Development Programs
by Zacks Equity Research
We issued an updated report on Agenus Inc. (AGEN) on Apr 4.
Bristol-Myers (BMY), Incyte to Advance Clinical Program
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) and Incyte Corporation (INCY) recently announced that the companies will advance their clinical development program.
Zacks.com featured highlights: PTC, Covanta Holding, Etsy, Incyte and AMAG Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights: PTC, Covanta Holding, Etsy, Incyte and AMAG Pharmaceuticals
5 Toxic Stocks to Get Rid Of or Play Short to Make Gains
by Zacks Equity Research
Exaggerated price of toxic stocks can be attributed to either an irrational exuberance associated with them or some serious fundamental lacuna.
Incyte (INCY) Up 26.2% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals
5 Toxic Stocks to Dump or Play Short to Make Gains
by Zacks Equity Research
Unreasonably high price of toxic stocks is only short-lived as the intrinsic value of these stocks is lower than the current bloated price.
Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Agenus Inc. (AGEN) reported fourth-quarter 2016 loss of 30 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 33 cents but wider than the year-ago loss of 18 cents.
A Trip to 8-Year Bull Run: What's Up, What's Down
by Sweta Killa
While all the three major indices more than tripled scaling multiple highs in recent months, Nasdaq has won the maximum in the eight-year bull run.
5 Toxic Stocks to Abandon or Play Short Right Now
by Zacks Equity Research
In general, toxic stocks are burdened with huge debt loads and vulnerable to external shocks.
What's Driving Lilly's (LLY) Shares after 2016 Decline?
by Zacks Equity Research
After a rather difficult 2016, share price of pharma giant, Eli Lilly & Company (LLY) has picked up in 2017.
Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook
by Zacks Equity Research
Incyte Corporation (INCY) reported fourth-quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents.
Lilly's Olumiant Gets Marketing Authorization in Europe
by Zacks Equity Research
Eli Lilly and Company (LLY) along with its partner Incyte Corporation (INCY) announced that the European Commission has granted marketing authorization to once-daily baricitinib in Europe.
The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences